GMDP for psoriasis

Lancet. 1998 Aug 15;352(9127):545. doi: 10.1016/S0140-6736(05)79253-9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acetylmuramyl-Alanyl-Isoglutamine / administration & dosage
  • Acetylmuramyl-Alanyl-Isoglutamine / adverse effects
  • Acetylmuramyl-Alanyl-Isoglutamine / analogs & derivatives*
  • Acetylmuramyl-Alanyl-Isoglutamine / therapeutic use
  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / adverse effects
  • Adjuvants, Immunologic / therapeutic use*
  • Administration, Oral
  • Follow-Up Studies
  • Humans
  • Pain / etiology
  • Pruritus / therapy
  • Psoriasis / classification
  • Psoriasis / pathology
  • Psoriasis / therapy*
  • Severity of Illness Index
  • T-Lymphocyte Subsets / pathology
  • Vomiting / etiology

Substances

  • Adjuvants, Immunologic
  • Acetylmuramyl-Alanyl-Isoglutamine
  • glucosaminylmuramyl-2-alanine-D-isoglutamine